
Carola Rong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3069764/publications.pdf

Version: 2024-02-01



CAROLA RONC

#	Article	IF	CITATIONS
1	Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 655.	2.6	150
2	Cognitive impairment in major depressive disorder. CNS Spectrums, 2019, 24, 22-29.	1.2	125
3	Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacological Research, 2017, 121, 213-218.	7.1	102
4	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. International Journal of Environmental Research and Public Health, 2018, 15, 771.	2.6	80
5	Drug-drug interactions as a result of co-administering Δ ⁹ -THC and CBD with other psychotropic agents. Expert Opinion on Drug Safety, 2018, 17, 51-54.	2.4	64
6	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. Journal of Affective Disorders, 2017, 222, 14-20.	4.1	39
7	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. Reviews in the Neurosciences, 2018, 30, 1-7.	2.9	35
8	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Annals of Clinical Psychiatry, 2018, 30, 38-50.	0.6	28
9	Serum metabolic profiling using small molecular waterâ€soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre–postâ€ŧreatment design. Psychiatry and Clinical Neurosciences, 2019, 73, 100-108.	1.8	20
10	Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. Expert Opinion on Investigational Drugs, 2019, 28, 113-119.	4.1	20
11	Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. CNS and Neurological Disorders - Drug Targets, 2018, 16, 891-899.	1.4	18
12	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). Journal of Psychiatric Research, 2021, 135, 311-317.	3.1	15
13	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 475-482.	3.3	12
14	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. Journal of Affective Disorders, 2018, 238, 228-232.	4.1	11
15	The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. Perspectives in Psychiatric Care, 2018, 54, 507-513.	1.9	9
16	Intracellular Signaling Cascades in Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 101-132.	1.7	9
17	Does obesity and diabetes mellitus metastasize to the brain? "Metaboptosis―and implications for drug discovery and development. CNS Spectrums, 2019, 24, 467-469.	1.2	5
18	The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. Journal of Affective Disorders, 2022, 308, 71-75.	4.1	4

CAROLA RONG

#	Article	IF	CITATIONS
19	A case of mirror image agnosia and mirrored self-misidentification syndrome in schizophrenia without dementia or structural abnormalities. Neurocase, 2020, 26, 317-319.	0.6	1
20	A Novel Refractory Mood Disorders and Electroconvulsive Therapy Elective for Medical Students: Fighting Stigma through Experience. Psychiatric Quarterly, 2021, 92, 1541-1548.	2.1	1
21	13-Month maintenance ECT treatment in a 66-year-old male patient with pacemaker. , 2022, 1, 100005.		Ο